Reviewing Aclarion (NASDAQ:ACON) & Phreesia (NYSE:PHR)

Aclarion (NASDAQ:ACON) and Phreesia (NYSE:PHR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Institutional and Insider Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 92.1% of Phreesia shares are held by institutional investors. 0.0% of Aclarion shares are held by company insiders. Comparatively, 5.2% of Phreesia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Aclarion has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Phreesia has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Aclarion and Phreesia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Phreesia	2.06%	5.22%	3.02%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aclarion and Phreesia, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Phreesia	1	10	8	0	2.37

Aclarion currently has a consensus target price of $7.50, suggesting a potential upside of 189.58%. Phreesia has a consensus target price of $14.00, suggesting a potential upside of 37.59%. Given Aclarion’s higher possible upside, equities analysts clearly believe Aclarion is more favorable than Phreesia.

Valuation and Earnings

This table compares Aclarion and Phreesia”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	93.24	-$7.23 million	($7.40)	-0.35
Phreesia	$480.59 million	1.31	$2.31 million	$0.17	59.85

Phreesia has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.

Summary

Phreesia beats Aclarion on 11 of the 14 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Phreesia

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.